


Introduction to Epidemiology and Genetic Epidemiology

ep·i·de·mi·ol·o·gy


/,epə,dēmē'äləjē/

noun

the branch of medicine that deals with the incidence, distribution, and possible control of diseases and other factors relating to health.



Cohort vs. case-control studies



Copyright © 2006 Nature Publishing Group
Nature Reviews | Genetics

Estimated incidence rates in cohorts

Disease incidence per 100,000 per year (%)	Disease examples	Number of incident cases in 5 years for different cohort sizes		
		200,000	500,000	1,000,000
10 (0.01)	Parkinson disease, schizophrenia	91	228	457
50 (0.05)	Colorectal cancer, renal failure	456	1,141	2,282
100 (0.10)	Breast cancer, hip fracture	912	2,279	4,559
200 (0.20)	Diabetes, stroke, heart failure	1,820	4,550	9,100
500 (0.50)	Myocardial infarction, all cancers	4,524	11,309	22,618
3,000 (3.00)	Cataracts, hypertension	25,858	64,644	129,289

Estimated numbers of incident cases available after 5 years of follow-up across the entire age range in the US population are shown, assuming an attrition rate of 3% per year. Data are taken from the Incidence and Prevalence Database.

Manolio. *Nature Reviews Genetics* 2006

Compared to cohorts, case-control studies are cheap, fast and powerful

However, case-control studies suffer from several drawbacks:

the need to identify appropriate controls

they are more sensitive to recall bias

Association and Causality

- An exposure and outcome are associated if there is a differential distribution:
 - The prevalence of exposure differs between cases and controls.
 - An exposure is causal for the outcome if the presence (or absence) of the exposure directly or indirectly influences whether the outcome occurs.

THE FAMILY CIRCUS





"I wish they didn't turn on that seatbelt sign so much! Every time they do, it gets bumpy."

Sources of bias in epidemiology

- **Selection Bias**
 - Arises when cases and controls are coming from different source populations (e.g. female cases, male controls)
- **Survival bias**
 - When cases are recruited some time after they were diagnosed. Might lead to a milder form of disease. This is especially true for aggressive/fatal disease (e.g. pancreatic cancer, heart attack)
- **Diagnostic bias**
 - If the investigator determining the outcome knows whether the person was exposed or not to the risk factor under study (e.g. if the radiologist knows that a potential pulmonary disease patient smokes, she may look more carefully at the x-ray).
- **Recall bias**
 - Accuracy and completeness of exposures, life-style behaviors etc (e.g. cases might be more motivated to complete a questionnaire accurately).


Confounding

- A confounder is often defined as a factor that is:
 - ① A risk factor for the disease
 - ② Associated with the exposure
 - ③ Not a direct result of the exposure
- Confounding can lead to false positive findings.



BREAKOUT ACTIVITY

Confounding example: Birth order and Down syndrome



Data from Stark and Mantel (1966)

Source: Rothman 2002

1. Can you think of a factor that would confound the observed association?
2. How can you use data on your proposed confounding factor to reassess the association between birth order and Down Syndrome?
3. Can you think of potential confounders in genetic epidemiology?

Genetic Epidemiology

***Genetic epidemiology** is the study of the role of **genetic** factors in determining health and disease in families and in populations, and the interplay of such **genetic** factors with environmental factors.*



**Ed was unlucky enough to find
the needle in the haystack!**

April 13, 2007

'Fat' gene found by scientists



Mark Henderson, Science Editor

A gene that contributes to obesity has been identified for the first time, promising to explain why some people easily put on weight while others with similar lifestyles stay slim.

[Recommend 414](#) [Share](#) [Tweet](#)



Brain-Aging Gene Discovered

Genetic variant accelerates normal brain aging in older people by up to 12 years

March 15, 2017

Posted in: [Neurology](#) / [Medicine](#)

Smoking addiction gene found

Scientists say a gene makes people more likely to get hooked on tobacco, causing them to smoke more, making it harder to quit, and leading more often to deadly lung cancer. [Full story](#)

[Newsweek: Differing conclusions](#)


[Researchers make human-cow embryos](#)

[Science wishy-washy on water benefits](#) | [Vote](#)




Does aspirin prevent colorectal cancer? Depends on your DNA

Why do we want to study how our genome is involved in disease?



Why do we want to study how our genome is involved in disease?



OP-ED CONTRIBUTOR

My Medical Choice

By ANGELINA JOLIE

Published: May 14, 2013 | 1712 Comments

LOS ANGELES

[Enlarge This Image](#)



Loren Capelli

MY MOTHER fought cancer for almost a decade and died at 56. She held out long enough to meet the first of her grandchildren and to hold them in her arms. But my other children will never have the chance to know her and experience how loving and gracious she was.

We often speak of “Mommy’s mommy,” and I find myself trying to explain the illness that took her away from us. They have asked if the same could happen to me. I have always told them not to worry, but the truth is I carry a “faulty” gene, BRCA1, which sharply increases my risk of developing breast cancer and ovarian cancer.

FACEBOOK

TWITTER

GOOGLE+

SAVE

E-MAIL

SHARE

PRINT

REPRINTS

**Enough Said
Now Playing**

TIME

MAY 27, 2013

THE ANGELINA EFFECT


Angelina Jolie's double mastectomy puts genetic testing in the spotlight. What her choice reveals about calculating risk, cost and peace of mind

BY JEFFREY KLUGER & ALICE PARK

time.com


NATIONAL CANCER INSTITUTE CHANCES OF DEVELOPING BREAST CANCER BY AGE 70

Specific inherited mutations in the BRCA1 and BRCA2 genes increase the risk of breast and ovarian cancers. Testing for these mutations is usually recommended in women without breast cancer only when the person's individual or family history suggests the possible presence of a harmful mutation in BRCA1 or BRCA2. Testing is often recommended in younger women newly diagnosed with breast cancer because it can influence treatment decisions and have implications for their family members.




MUTATED BRCA1

55-65%





MUTATED BRCA2

45%




NORMAL BRCA

12%



Association between a genetic risk score of 313 common variants and breast cancer risk in women of European origin



“The average 10-year absolute risk of breast cancer for a 47-year-old woman (the age at which women become eligible to enter the UK breast cancer screening program) in the general population is 2.6%. However, the 19% of women with highest genetic risk will attain this level of risk by age 40 years”

23andMe Granted First FDA Authorization for Direct-to-Consumer Genetic Test on Cancer Risk

March 6, 2018

Authorization allows 23andMe to report on BRCA1- and BRCA2-related genetic risk for breast, ovarian and prostate cancer

Mountain View, California – March 6, 2018 – 23andMe, Inc., the leading personal genetics company, today received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk. The authorization allows 23andMe to provide customers, without a prescription, information on three genetic variants found on the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian and prostate cancer.

“Being the first and only direct-to-consumer genetics company to receive FDA authorization to test for cancer risk without a prescription is a major milestone for 23andMe and for the consumer,” said Anne Wojcicki, 23andMe CEO and co-founder. “We believe it’s important for consumers to have direct and affordable access to this potentially life-saving information. We will continue pioneering a path for greater access to health information, and promoting a more consumer-driven, preventative approach to health care.”

23andMe will report on three variants in the BRCA1 and BRCA2 genes associated with a significantly higher risk of breast and ovarian cancer in women, and breast cancer in men. The variants may also be associated with an increased risk for certain other cancers. These variants are

23andMe Receives FDA Clearance for Genetic Health Risk report that looks at a Hereditary Colorectal Cancer Syndrome

January 22, 2019 By 23andMe under Health and Traits

23andMe received FDA clearance to report on the two most common genetic variants influencing what is called MUTYH-associated polyposis (MAP), a hereditary colorectal cancer syndrome.

This new clearance is part of 23andMe’s ongoing efforts to work with the FDA to offer additional Genetic Health Risk reports as part of its Health + Ancestry Service.

“We are committed to giving people affordable direct access to important health information that can impact their lives,” said Anne Wojcicki, 23andMe CEO and co-founder.

The MAP report is not yet available, but as soon as it is, 23andMe will offer it to Health + Ancestry Service customers as well as to customers genotyped on the company’s most comprehensive (Selected Variants) Genetic Health Risk report. Customers who want to receive this information.



23andMe Offers New Genetic Report on Type 2 Diabetes

March 10, 2019 By 23andMe under Health and Traits

23andMe’s new Type 2 Diabetes report* offers customers insight into their likelihood of developing one of the most prevalent, pernicious, and yet preventable health conditions in the United States.

This new report will impact more 23andMe customers than any other Health + Ancestry Predisposition report the company has ever released. In part, this is because the likelihood of developing [type 2 diabetes](#) is so high in the general population.

“Diabetes is a significant health issue in the United States that is expected to impact nearly half of the population,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “When customers learn about their genetic likelihood of developing type 2 diabetes, we believe there is an opportunity to motivate them to change their lifestyle and ultimately to help them prevent the disease.”

Rising Rates of Diabetes


In the United States alone, where rates of obesity have ratcheted up in recent decades, a staggering one in three Americans have prediabetes, according to estimates from [the U.S. Centers for Disease Control and Prevention](#). Worse, 90 percent don’t know they have it. The impact is even greater among certain



What’s a Polygenic Score?

The genes we inherit from our mother and father influence our risk of disease. While that’s pretty straightforward, the role genetics plays is a bit more complicated.

Why do we want to study how our genome is involved in disease?



“Association does not imply causation”



HDL (“Good”) Cholesterol and Myocardial Infarction (MI)

- **↑** HDL -> **↓** MI risk




Increasing HDL concentrations
might help decrease
cardiovascular disease risk.




People who carry gene variants that increase HDL do not have a lower risk of MI

Since HDL is correlated with exercise, weight loss, diet (nuts, fish) it is likely that these lower your risk for MI rather than HDL itself



Why do we want to study how our genome is involved in disease?




Rheumatoid Arthritis – an inflammatory, crippling, incurable disease

- In 2005, an estimated 1.5 million (0.6%) of US adults age ≥ 18 had RA.





A study of 10 million genetic variants in 29,880 RA cases and 73,758 controls

b



Identified genes are targets of approved therapies for RA, and further suggest that drugs approved for other diseases may be repurposed for the treatment of RA

flavopiridol



Cancers/psoriasis

Breast cancer

NDC 0069-0189-21

IbranceTM
(palbociclib)
capsules

125 mg

For Oncology Use Only
21 Capsules **Rx only**

Lymphoma/Leukemia/Liver cancer

Okada, Nature, 2014

BREAKOUT ACTIVITY:

What would you say to this patient?

